Pune Divisional Commissioner Saurav Rao has confirmed the news that Prime Minister Narendra Modi will be visiting Pune's Serum Institute of India (SII) on November 8. The purpose of the visit is to review and examine ‘Covishield’ vaccine development work.
The ‘Covishield’ vaccine candidate is being developed by British-Swedish pharmaceutical firm AstraZeneca in collaboration with UK's Oxford University and SII has partnered with them for the manufacturing and distribution of its Covid-19 vaccine candidate 'Covishield' in India.
Earlier this week, Oxford-AstraZeneca has announced that its Covid-19 vaccine candidate has shown 70 per cent efficiency and that the vaccine can produce 90 per cent effectiveness under "one dosing regimen".
"Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens," said the press note released by the Oxford University.
According to the interim trial data from the phase III trials released by the company said that the two different dose regimens, vaccine efficacy was 90% in one, and 62% in the other.
The company also added, "Early indication that vaccine could reduce virus transmission from an observed reduction in asymptomatic infections.”
The company further stated that there was no hospitalisation or severe crises occurred in anyone on whom the vaccine was injected while the company wait for the results of Phase three trials.
'Covishield' vaccine candidate has been given to thousands of people around the world and everyone is eyeing whether their vaccine is safe and effective.